Spots Global Cancer Trial Database for CC-5013 in Treating Patients With Recurrent Glioma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: CC-5013 in Treating Patients With Recurrent Glioma

Official Title: A Phase I Trial Of A Thalidomide Analog, CC-5013, For The Treatment Of Patients With Recurrent High-Grade Gliomas

Study ID: NCT00036894

Conditions

Brain and Central Nervous System Tumors

Interventions

lenalidomide

Study Description

Brief Summary: RATIONALE: CC-5013 may stop the growth of gliomas by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have recurrent glioma.

Detailed Description: OBJECTIVES: * Determine the maximum tolerated dose of CC-5013 in patients with recurrent high-grade gliomas. * Determine the toxic effects of this drug in these patients. * Determine the pharmacokinetics of this drug in these patients. * Determine the antiangiogenic activity of this drug in these patients. OUTLINE: This is a dose-escalation study. Patients are stratified according to concurrent enzyme-inducing antiepileptic drugs (yes vs no). Patients receive oral CC-5013 weekly for 3 weeks. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of CC-5013 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients are followed at 2 weeks. PROJECTED ACCRUAL: A maximum of 80 patients (40 per stratum) will be accrued for this study within 20 months.